CanSinoBIO Charts New Course in Global Vaccine Equity and Innovation

DUBAI, UAE – February 09, 2026 – Amidst the global dialogues on shaping future governments, one biotechnology firm has taken a unique seat at the table, signaling a new chapter in public-private health diplomacy. For the second consecutive year, CanSino Biologics Inc. was the sole vaccine manufacturer invited to the prestigious World Government Summit (WGS) in Dubai, a platform where the company outlined an ambitious strategy that extends far beyond its widely recognized COVID-19 vaccine.

At the summit's "New Silk Road Forum," Chairman and CEO Dr. Xuefeng Yu articulated a vision centered on translating scientific breakthroughs into accessible solutions for the world's most pressing health challenges. "Guided by our mission to provide innovative, high-quality and affordable vaccines worldwide, CanSinoBIO continues to advance research and development with a focus on unmet public health needs," Dr. Yu stated, calling for strengthened international cooperation to ensure equitable access to medical innovation. This message, delivered from a unique position of influence, underscores the company's transition from a pandemic responder to a long-term architect of global health security.

Beyond the Pandemic: A New Generation of Vaccines

While CanSinoBIO’s early success with its WHO-listed adenovirus vector COVID-19 vaccine and the world's first inhaled version established its innovative capabilities, the company is now channeling that expertise toward a diverse pipeline of next-generation vaccines targeting some of humanity's oldest and most persistent diseases.

A key focus is the fight against tuberculosis (TB). Leveraging its groundbreaking inhaled delivery platform, the company initiated Phase I clinical trials for an inhaled TB vaccine in Indonesia in November 2025. This needle-free approach aims to induce a powerful immune response directly in the respiratory tract, a potentially revolutionary method for controlling a disease that claims over a million lives annually. The trials followed successful earlier studies in Canada that demonstrated the vaccine's safety and superior ability to boost mucosal immunity.

Simultaneously, CanSinoBIO is tackling the final, formidable challenge of global polio eradication. Its recombinant polio vaccine, VLP-Polio, is a front-runner candidate recognized by the World Health Organization. The vaccine’s most significant innovation is its production process, which is based on virus-like particle assembly and does not involve any live poliovirus, thereby eliminating the risk of vaccine-derived polio outbreaks and reducing biosafety hazards at the source. Supported by over $17 million in funding from the Bill & Melinda Gates Foundation, the VLP-Polio vaccine is currently undergoing clinical trials in Indonesia, representing a critical step toward a safer post-eradication world.

The company is also making significant inroads into the pneumococcal disease market. Its recombinant pneumococcal protein vaccine (PBPV) has shown positive preliminary results in Phase I trials. Designed to be serotype-independent, the PBPV aims to provide coverage against at least 98% of pneumococcal strains—a substantial advantage over existing conjugate vaccines that face challenges with serotype replacement. With a simpler production process promising greater scalability and affordability, the PBPV could become a vital tool for sustainable immunization programs, especially in resource-limited nations.

Building Bridges: A Strategy of Global Collaboration

Underpinning CanSinoBIO's technological ambition is a sophisticated and expanding network of international partnerships. The company is moving beyond traditional export models to foster deep collaboration, including technology transfer, joint R&D, and localized manufacturing, thereby embedding itself within the public health ecosystems of key emerging markets.

In Indonesia, a partnership with PT Etana Biotechnologies is driving the clinical development of the inhaled TB vaccine and exploring local fill-and-finish capabilities, aligning with Indonesia’s goal of becoming a regional biotech hub. The country has also officially registered CanSinoBIO's quadrivalent meningococcal conjugate vaccine, Menhycia®.

In Malaysia, the company is collaborating with the National Institutes of Biotechnology Malaysia (NIBM) to develop the nation’s first multivalent mRNA influenza vaccine. This follows an earlier successful partnership with Solution Biologics, which established a GMP-certified fill-and-finish facility with a capacity of 36 million vials annually, positioning Malaysia as a key production center for the ASEAN region.

The strategy extends to the Middle East, where a partnership with Saudi Arabia’s SPIMACO focuses on the commercialization and potential localized production of the Menhycia® vaccine. This is particularly crucial for the region, where the vaccine is mandatory for Hajj and Umrah pilgrims and is part of the national childhood immunization schedule.

Further west, a 2024 Memorandum of Understanding with the Butantan Institute, Brazil’s largest vaccine producer, paves the way for joint development of innovative vaccines and mRNA technology, building on previous agreements to distribute CanSinoBIO's products in Latin America's largest market.

Fueling Innovation and Navigating a Competitive Field

This global expansion is powered by robust financial health and a steadfast commitment to research. In 2024, CanSinoBIO reported a remarkable 137% year-on-year revenue increase to RMB 846 million, reflecting its successful transition into a commercial-stage biopharma entity. This financial strength allows for sustained investment across its five advanced technology platforms and a pipeline targeting over ten infectious diseases.

While entering crowded markets for polio and pneumococcal vaccines, dominated by giants like Pfizer, GSK, and Sanofi, CanSinoBIO's strategy relies on clear technological differentiation. Its VLP-Polio vaccine addresses critical safety concerns for the endgame of eradication, while its PBPV offers the promise of broader, more durable protection against pneumococcal disease. In the nascent field of inhaled vaccines, the company holds a significant first-mover advantage.

This forward-looking strategy was emphasized by Chief Commercial Officer Ms. Jeanne Wang at the WGS. "The WGS provides us a vital platform for deepening global cooperation," she stated. "CanSinoBIO will continue to advance its international commercial expansion, strengthen collaboration with governments, international organizations and local partners across countries, explore diverse cooperation models, and accelerate the accessibility and implementation of innovative vaccines in more nations and regions, all to better serving global public health needs." As it forges these global partnerships, the company is not just selling products but co-creating a more resilient and equitable global health infrastructure.